CABERGOLINE Drug Patent Profile
✉ Email this page to a colleague
When do Cabergoline patents expire, and when can generic versions of Cabergoline launch?
Cabergoline is a drug marketed by Actavis Labs Fl Inc, Apotex Corp, Impax Labs Inc, Ingenus Pharms Llc, Ivax Sub Teva Pharms, Mylan, and Strides Pharma. and is included in seven NDAs.
The generic ingredient in CABERGOLINE is cabergoline. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cabergoline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cabergoline
A generic version of CABERGOLINE was approved as cabergoline by STRIDES PHARMA on December 29th, 2005.
Summary for CABERGOLINE
| US Patents: | 0 |
| Applicants: | 7 |
| NDAs: | 7 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 64 |
| Clinical Trials: | 58 |
| Patent Applications: | 5,393 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CABERGOLINE |
| What excipients (inactive ingredients) are in CABERGOLINE? | CABERGOLINE excipients list |
| DailyMed Link: | CABERGOLINE at DailyMed |
Recent Clinical Trials for CABERGOLINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Aarhus | N/A |
| xiaolong zhao | N/A |
| HaEmek Medical Center, Israel | N/A |
Pharmacology for CABERGOLINE
| Drug Class | Ergot Derivative |
Anatomical Therapeutic Chemical (ATC) Classes for CABERGOLINE
US Patents and Regulatory Information for CABERGOLINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Labs Fl Inc | CABERGOLINE | cabergoline | TABLET;ORAL | 078035-001 | Apr 21, 2008 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Strides Pharma | CABERGOLINE | cabergoline | TABLET;ORAL | 076310-001 | Dec 29, 2005 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Ingenus Pharms Llc | CABERGOLINE | cabergoline | TABLET;ORAL | 204735-001 | Aug 1, 2018 | AB | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Apotex Corp | CABERGOLINE | cabergoline | TABLET;ORAL | 201503-001 | Mar 8, 2013 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for CABERGOLINE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Ceva Santé Animale | Velactis | cabergoline | EMEA/V/C/003739 For use in the herd management programme of dairy cows as an aid in the abrupt drying-off by reducing milk production to:reduce milk leakage at drying off;reduce the risk of new intramammary infections during the dry period;reduce discomfort. |
Withdrawn | no | no | no | 2015-12-09 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
